Unique Clinical Maestro Platform Efficiently Budgets, Sources, and Manages Complex Clinical Studies
San Francisco, CA – April 25, 2023 – Strategikon Pharma, a leading provider of innovative clinical business solutions, is pleased to announce that it has won the Acquisition International 2023 Award for the Best End-to-End Clinical Business Operations Solution.
The Acquisition International Awards are presented to companies that have shown excellence in their respective fields and have demonstrated innovative and transformative practices. The award is given after thorough evaluation of various factors, including innovation, growth, customer satisfaction, and industry impact. Winning this prestigious award is a testament to Strategikon Pharma’s commitment to excellence and innovation in the clinical business operations space.
Strategikon Pharma’s end-to-end clinical business operations solution is designed to optimize clinical operations and simplify complex processes for its clients. This comprehensive solution covers the entire clinical trial lifecycle, from study design and planning to patient recruitment and retention, data management, and regulatory compliance. By providing a full suite of integrated services, Strategikon Pharma delivers significant value to its clients, reducing operational costs, increasing efficiency, and improving overall outcomes.
“We are thrilled to receive the Acquisition International Award for the Best End-to-End Clinical Business Operations Solution,” said Anca Copaescu, CEO of Strategikon Pharma. “This award is a testament to our commitment to delivering world-class solutions that cater to the ever-evolving needs of clinical business operations. We are grateful for the recognition and the opportunity to continue serving our customers with a high level of dedication and excellence.”
“This honor comes on the heels of having won the Venture Madness Conference Competition 2023,” she continued. “It recognizes the most innovative and promising startups, based on their potential for growth, products, and services offered, market size, and impact on the industry. This award is a significant accomplishment for us, and we are proud to be among the most promising startups of the year.”
We are thrilled to have won the Venture Madness Conference Competition 2023, which recognizes the most innovative and promising startups, based on their potential for growth, products, and services offered, market size, and impact on the industry. This award is a significant accomplishment for us, and we are proud to be among the most promising startups of the year. Strategikon’s innovative solutions and dedication to its clients have earned it a reputation as a trusted partner in the pharmaceutical industry. The Acquisition International Award for the Best End-to-End Clinical Business Operations Solution further validates the company’s position as a leader in the field.
To learn more about the latest Clinical Maestro innovations, join us for our webinar “Groundbreaking Functionality for Biopharmaceutical Outsourcing” to be broadcast live on May 3, at 12pm EST.
About Clinical Maestro by Strategikon
Clinical Maestro is a SaaS solution that equips all participants in developing clinical trials, including both Biopharmaceutical companies and R&D Service Providers with state-of-the-art tools to budget, source, and manage faster, more accurately, and with less effort. Please visit www.clinicalmaestro.com for more details.
